Experiences with the use of oxaliplatin in esophageal carcinoma
| Autor: | Magnus Bergenfeldt, Lianna Kadar, Maria Albertsson |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Endoscopic ultrasound
medicine.medical_specialty medicine.diagnostic_test business.industry medicine.medical_treatment Locally advanced Mean age Hematology General Medicine medicine.disease Endoscopy Surgery Oxaliplatin Radiation therapy Oncology Concomitant Carcinoma medicine Radiology Nuclear Medicine and imaging business medicine.drug |
| Zdroj: | Acta Oncologica. 45:103-105 |
| ISSN: | 1651-226X 0284-186X |
| DOI: | 10.1080/02841860500372319 |
| Popis: | 10%) [1]. When the diagnosis is made,approximately 50% of patients are not candidates forcurative therapy due to locally advanced disease ormetastases. In this group of patients, median survivaltime is 6 months or less with or without palliativetreatment [2]. To date, the treatment of choice inadvanced esophageal carcinoma has been cisplatinand 5-FU with concomitant radiotherapy [3,4]. Asecond-generation platinum analogue, oxaliplatin,seems to have comparable or possibly even bettertherapeutic effect with substantially fewer sideeffects [5]. In this study, we report our initialexperience with the use of oxaliplatin in advancedesophageal carcinoma.The study included twenty consecutive patients(8 women, 12 men) with locally advanced esopha-geal carcinoma patients at the Department ofOncology, University Hospital of Malmo¨, Swedenbetween June 2000 and April 2002. Diagnosis andstaging were established through endoscopy withbiopsies, thoracoabdominal computerized tomogra-phy and endoscopic ultrasound. Mean age was64 years (range 46 radiation dose of 40 Gy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|